---
title: 'Consensus guidelines and recommendations for the management and response assessment
  of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and
  refractory multiple myeloma: a report from the International Myeloma Working Group
  Immunotherapy Committee'
date: '2024-05-31'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38821074/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&fc=20220923065203&ff=20240601181045&v=2.18.0.post9+e462414
source: (((leukemia) OR (lymphoma)) OR (myeloma)) AND (Stanford University[Affiliation])
description: 'Chimeric antigen receptor (CAR) T-cell therapy has shown promise in
  patients with late-line refractory multiple myeloma, with response rates ranging
  from 73 to 98%. To date, three products have been approved: Idecabtagene vicleucel
  (ide-cel) and ciltacabtagene autoleucel (cilta-cel), which are approved by the US
  Food and Drug Administration, the European Medicines Agency, Health Canada (ide-cel
  only), and Brazil ANVISA (cilta-cel only); and equecabtagene autoleucel (eque-cel),
  which was ...'
disable_comments: true
---
Chimeric antigen receptor (CAR) T-cell therapy has shown promise in patients with late-line refractory multiple myeloma, with response rates ranging from 73 to 98%. To date, three products have been approved: Idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel), which are approved by the US Food and Drug Administration, the European Medicines Agency, Health Canada (ide-cel only), and Brazil ANVISA (cilta-cel only); and equecabtagene autoleucel (eque-cel), which was ...